EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
8/22/2022 | 2:50 PM - 3:15 PM | Tracking Clinical Outcomes of Infants Identified with Cytomegalovirus Infection in Neonatal Intensive | Governor General III
Tracking Clinical Outcomes of Infants Identified with Cytomegalovirus Infection in Neonatal Intensive
Objectives: To describe outcomes of infants reported with cytomegalovirus (CMV) infection in neonatal intensive care units (NICUs) in California during 2010-2021. Methods: We analyzed outcomes up to 3 years of age for infants with CMV (i.e., with a positive culture or PCR), who were reported by NICUs to the California Perinatal Quality Care Collaborative (CPQCC) and referred to a statewide high-risk infant follow-up (HRIF) program. HRIF criteria include birth <32 weeks of gestation, birth weight ?1500 grams, or neurological condition. Results: Of the 333 (1.9 per 1000) infants with CMV, 19 (6%) died in the neonatal period. Among survivors, 272 (87%) were referred for HRIF and 203 (75%) had ?1 visit. Among 145 infants with CMV with a second HRIF visit (median age: 13 months), 12% had bilateral blindness and 12% had hearing loss. Among 103 infants with a third HRIF visit (median age: 26 months), 5% had severe cerebral palsy. Among infants with CMV referred to HRIF, proportions with ?1 visit were lowest among infants born to mothers <20 years or of Hispanic origin. Conclusions: Linked data from CPQCC and the HRIF program in California are useful for assessing CMV disease burden and will help inform surveillance efforts.
- Identify key variables for data collection for CMV surveillance in California
- Examine clinical outcomes of infants with CMV infection
- Compare follow-up rates of infants with CMV infection across different demographic groups
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Tatiana Lanzieri
(), uyk4@cdc.gov;
Tatiana M. Lanzieri, M.D., M.P.H., is a medical epidemiologist with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention. She has over 20 years of experience in infectious disease epidemiology, surveillance, and outbreak investigation.
ASHA DISCLOSURE:
Financial -
Nonfinancial -